Back Bay Life Science Advisors

Back Bay Life Science Advisors integrates strategy consulting with investment banking for global life sciences, providing strategic guidance and responsive client service across commercial, R&D, corporate business development, and investment banking opportunities. Founded in 2010 and based in Boston with a new office in Toronto’s MaRS Discovery District, the company has completed over 750 projects and transactions in BioPharma and MedTech. They have a strategic partnership with DNB Bank to drive global healthcare growth and innovation, and a strong track record in Europe, particularly in the Nordics, UK, France, Belgium, Netherlands, Germany, Switzerland, and Italy. Specializing in US-EU life sciences partnerships, Back Bay Life Science Advisors emphasizes the Nordic region and offers services such as strategic advisory, analytics, investment banking, and global partnerships. Their dedicated investment banking team has more than $23 billion in transactional experience. The company has been recognized as a top consulting firm in the country and has expertise in life sciences product, pipeline, and lifecycle advisory. Significant transactions include the licensing of Centrexion’s non-opioid pain asset to Eli Lilly for $47.5M upfront and up to $950M in milestones. They provide weekly healthcare market updates and have published white papers on various topics, including drug development in obesity, radiopharmaceuticals, and cell technology. Additionally, Back Bay Life Science Advisors hosts the Nordic-American Healthcare Conference, a leading US-Nordic healthcare public equity investor conference.